International Journal of Hematology

Papers
(The H4-Index of International Journal of Hematology is 19. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
Differences in longitudinal growth patterns of children and adolescents with transfusion-dependent hemoglobin E/β-thalassemia and those achieving successful hematopoietic stem-cell transplantation91
Comparison between filgrastim biosimilar and filgrastim original for the management of neutropenia after salvage chemotherapy for malignant lymphoma58
Acute suppression of translation by hyperthermia enhances anti-myeloma activity of carfilzomib56
Carcinocythemia diagnosed on peripheral blood clot sections37
NOVEL-1st: an observational study to assess the safety and efficacy of nilotinib in newly diagnosed patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase in Taiwan35
Real-world treatment patterns and clinical outcomes in patients with AML in Japan who were ineligible for first-line intensive chemotherapy27
Coexpression of natural killer cell antigens by T-cell large granular lymphocytes in hydroa vacciniforme lymphoproliferative disorder and the involvement of Vδ1 + epithelial-type γδT cells26
Post-transfusion purpura and adult primary thrombocytopenia26
Acute myeloid leukemia with NUP98::RARG rearrangement: a case report and review of the relevant literature25
Asciminib in patients with newly diagnosed chronic myeloid leukemia: results from the Japanese subgroup of ASC4FIRST25
Changes in coagulation potential over time after administration of recombinant activated factor VII in an emicizumab-treated hemophilia A patient with inhibitors24
Advances in immune microenvironment profiling during multiple myeloma progression and therapy23
IBRORS-MCL study: a Spanish retrospective and observational study of relapsed/refractory mantle-cell lymphoma treated with ibrutinib in routine clinical practice23
Real-world toxicity and effectiveness of ixazomib, lenalidomide, and dexamethasone in Korean patients with relapsed and/or refractory multiple myeloma21
CEBPA mutations in acute myeloid leukemia: implications in risk stratification and treatment21
WT1-guided pre-emptive therapy after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia21
Ex vivo manufacturing of platelets: beyond the first-in-human clinical trial using autologous iPSC-platelets20
EVI1 upregulates PTGS1 (COX1) and decreases the action of tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia cells20
Hexokinase II expression as a prognostic marker in diffuse large B-cell lymphoma: pre- and post-rituximab era19
0.17988896369934